Yes, and no. The company has said they will use date from the Rosacea Ph2 to build on Acne Ph3, but there is no reason anti-microbial couldn't run simultaneously to either acne or rosacea, other than funding. It speaks for itself that we are currently not running ANY trials whilst waiting approval for Sofdra, ONLY because we don't have the funds - nothing to do with evidence & learning. It will be the same going forward (other than the rosacea/acne connection acknowledged), but I daresay if we had the funds, you would see more than one trial on the go.
BOT - Anything but charting, page-6928
-
- There are more pages in this discussion • 3,349 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.005(1.19%) |
Mkt cap ! $751.1M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 40.0¢ | $2.133M | 5.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 51664 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 341870 | 4 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |